Wyeth OTC Loratadine Launch Unaffected By ANDA Exclusivity Issues – Exec
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Healthcare, which reported sluggish third quarter sales, could experience a big revenue boost late in Q4 if its plans to launch OTC loratadine upon expiration of Schering-Plough's patent remain on track